Cerebral Metabolic Differences Associated with Cognitive Impairment in Parkinson's Disease

PLoS One. 2016 Apr 11;11(4):e0152716. doi: 10.1371/journal.pone.0152716. eCollection 2016.

Abstract

Purpose: To characterize cerebral glucose metabolism associated with different cognitive states in Parkinson's disease (PD) using 18F-fluorodeoxyglucose (FDG) and Positron Emission Tomography (PET).

Methods: Three groups of patients were recruited in this study including PD patients with dementia (PDD; n = 10), with mild cognitive impairment (PD-MCI; n = 20), and with no cognitive impairment (PD-NC; n = 30). The groups were matched for age, sex, education, disease duration, motor disability, levodopa equivalent dose and Geriatric Depression Rating Scale (GDS) score. All subjects underwent a FDG-PET study. Maps of regional metabolism in the three groups were compared using statistical parametric mapping (SPM5).

Results: PD-MCI patients exhibited limited areas of hypometabolism in the frontal, temporal and parahippocampal gyrus compared with the PD-NC patients (p < 0.01). PDD patients had bilateral areas of hypometabolism in the frontal and posterior parietal-occipital lobes compared with PD-MCI patients (p < 0.01), and exhibited greater metabolic reductions in comparison with PD-NC patients (p < 0.01).

Conclusions: Compared with PD-NC patients, hypometabolism was much higher in the PDD patients than in PD-MCI patients, mainly in the posterior cortical areas. The result might suggest an association between posterior cortical hypometabolism and more severe cognitive impairment. PD-MCI might be important for early targeted therapeutic intervention and disease modification.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Brain / metabolism*
  • Brain / physiopathology
  • Cerebral Cortex / metabolism
  • Cerebral Cortex / physiopathology
  • Cognitive Dysfunction / etiology
  • Cognitive Dysfunction / metabolism*
  • Dementia / etiology
  • Dementia / metabolism*
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Levodopa / metabolism
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Parkinson Disease / complications
  • Parkinson Disease / metabolism*
  • Positron-Emission Tomography / methods

Substances

  • Fluorodeoxyglucose F18
  • Levodopa

Grants and funding

This research was financially supported by Grants (Nos. 81071018, 81171189, 81371413 and 81401135) from the National Natural Science Foundation of China.